From: Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis
Subgroup | No. of patients with mutant K-ras | No. of patients without mutant K-ras | HR (95 % CI) | Heterogeneity I 2 (%) | Heterogeneity P value |
---|---|---|---|---|---|
Ethnicity | |||||
Caucasian | 650 | 234 | 1.35 (1.10–1.63) | 28.0 | 0.195 |
Asian | 586 | 327 | 1.65 (1.32–1.72) | 0.0 | 0.136 |
Publication year | |||||
Before 2010 | 309 | 127 | 1.27 (0.96–1.69) | 33.1 | 0.175 |
After 2010 | 927 | 434 | 1.58 (1.36–1.83) | 0.0 | 0.963 |
Tumor resectability | |||||
Resectable | 594 | 301 | 1.44 (1.19–1.74) | 14.3 | 0.315 |
Unresectable | 586 | 241 | 1.57 (1.30–1.91) | 0.0 | 0.686 |
Treatment | |||||
Operation | 451 | 208 | 1.35 (1.09–1.69) | 35.7 | 0.183 |
Chemotherapy | 586 | 241 | 1.57 (1.30–1.91) | 0.0 | 0.686 |
Operation + chemotherapy | 143 | 93 | 1.71 (1.18–2.48) | 0.0 | 0.574 |
Detection methods | |||||
Sequencing | 428 | 235 | 1.57 (1.29–1.90) | 0.0 | 0.644 |
Other methods | 808 | 326 | 1.46 (1.22–1.75) | 2.0 | 0.421 |